Paloma Partners’s Acorda Therapeutics ACOR Stock Holding History

Paloma Partners’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-1,990	Closed	-$175K	–	2595
2020 Q2	$175K	Buy	+1,990	New	+$210K	﹤0.01%	1743
2020 Q1	–	Sell	-583	Closed	-$143K	–	2264
2019 Q4	$143K	Buy	583 +110	+23%	+$27.8K	﹤0.01%	2019
2019 Q3	$163K	Buy	+473	New	+$257K	﹤0.01%	1786
2018 Q4	–	Sell	-185	Closed	-$436K	–	1877
2018 Q3	$436K	Buy	+185	New	+$573K	0.01%	1085
2017 Q1	–	Sell	-323	Closed	-$729K	–	2312
2016 Q4	$729K	Buy	323 +144	+80%	+$342K	0.01%	1337
2016 Q3	$448K	Sell	179 -56	-24%	-$167K	0.01%	1467
2016 Q2	$719K	Buy	235 +34	+17%	+$111K	0.01%	1359
2016 Q1	$637K	Buy	+201	New	+$834K	0.01%	1182
2015 Q4	–	Sell	-76	Closed	-$243K	–	1986
2015 Q3	$243K	Buy	+76	New	+$295K	0.01%	1383
2015 Q2	–	Sell	-75	Closed	-$299K	–	1988
2015 Q1	$299K	Buy	+75	New	+$344K	0.01%	957
2014 Q4	–	Sell	-140	Closed	-$568K	–	1428
2014 Q3	$568K	Buy	+140	New	+$525K	0.03%	492

Other funds holding ACOR

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Parallax Volatility Advisers San Francisco, California $38.6B AUM 45.89% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Paloma Partners's ACOR Position: Q3 2020 in Review

Paloma Partners sold out of Acorda Therapeutics (ACOR) in Q3 2020, closing a stake of 1,990 shares — an estimated $175K sold.

Paloma Partners first reported a position in ACOR in Q3 2014 and held it in 11 quarters. The position peaked at $729K in Q4 2016. 60 funds tracked by Wall St. Rank hold ACOR as of Q3 2020.

Paloma Partners reported no remaining Acorda Therapeutics position as of Q3 2020 after selling out during the quarter.
Paloma Partners sold 1,990 Acorda Therapeutics shares in Q3 2020, an estimated $175K.
Paloma Partners first reported a position in Acorda Therapeutics in Q3 2014 and held it in 11 quarters.
Paloma Partners's Acorda Therapeutics position peaked at $729K in Q4 2016.
60 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q3 2020.

Based on Paloma Partners's 13F filing for Q3 2020, filed 16 Nov 2020.